Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and <i>BRCA1</i>/<i>2</i> Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

Melinda L. Telli(Stanford University), James M. Ford(Palo Alto University), Robert W. Carlson(National Comprehensive Cancer Network), Barbara Haley(Shaanxi Research Association for Women and Family), Kristin C. Jensen(Shaanxi Research Association for Women and Family), Kirsten M. Timms(Myriad (Germany)), Judith Manola(Dana-Farber Cancer Institute), Lori J. Goldstein(Shaanxi Research Association for Women and Family), Shaker R. Dakhil(Cancer Center of Kansas), Bobbie Head(Shaanxi Research Association for Women and Family), Allison W. Kurian(Stanford University), Victor Abkevich(Shaanxi Research Association for Women and Family), Patrick Flaherty(Shaanxi Research Association for Women and Family), Pei-Jen Chang(Shaanxi Research Association for Women and Family), Elizabeth Schackmann(Shaanxi Research Association for Women and Family), Irene Wapnir(Stanford Medicine), Joseph A. Sparano(Tisch Cancer Institute), Shaveta Vinayak(Roswell Park Comprehensive Cancer Center), Anne-Renee Hartman(Shaanxi Research Association for Women and Family), Julia Reid(Shaanxi Research Association for Women and Family), Jafi A. Lipson(Shaanxi Research Association for Women and Family)
Journal of Clinical Oncology
April 7, 2015
Cited by 226


Related Papers